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Despite promising results, the U.S. Food and Drug Administration (FDA) put on hold trials assessing anti-
nerve growth factor (a-NGF) compounds due to concerns over accelerated rates of OA progression. The
mechanism of these events is unclear but joint adverse events were observed particularly in patients
using a-NGFs in combination with non-steroidal anti-inﬂammatory drugs (NSAIDs), suggesting that the
signiﬁcantly greater analgesic effect of these separate classes of drugs prompted patients to permit
increased joint load without experiencing the usual pain that would limit joint stress. Development of a-
NGF drugs is continuing with stringent safety criteria included in future trials as a-NGF therapies offer
potential as the ﬁrst new class of analgesics in many years. Potential imaging joint safety ﬁndings and
exclusionary criteria for eligibility for the large weight bearing joints were presented in parts I and II of
this atlas.
The shoulder as a non-weight bearing joint is likely to be less affected by increased loading due to
efﬁcacious pain reduction. However, it remains prone to degeneration especially due to concomitant
rotator cuff pathology and previous trauma and inﬂammatory disorders. This third part of the atlas il-
lustrates imaging ﬁndings relevant for eligibility and potential joint safety ﬁndings such as osteonecrosis,
incidental ﬁndings such as large cystic lesions, inﬂammatory disorders, bone marrow disorders and
metastases.
© 2014 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.Introduction
Nerve growth factor (NGF) may increase the sensory nerve ac-
tivity in the subchondral bone, hence offering a mechanism for
both cartilage and subchondral bone as a peripheral source of pain
in osteoarthritis (OA) and may offer a target for treatment by a
novel class of drugs, the NGF inhibitors or a-NGFs1. A number of
novel a-NGF monoclonal antibody agents have been tested in
clinical trials for application in the treatment of pain in OA,
particularly of the hip and knee2,3.F.W. Roemer, Department of
GH Building, 3rd Floor, 820
4954; Fax: 1-617-638-6616.
g.de, froemer@bu.edu, frank.
lf of Osteoarthritis Research SocietThe most clinically advanced of this class, tanezumab, is a hu-
manized monoclonal antibody that binds and inhibits NGF and has
demonstrated both good analgesic efﬁcacy and improvement in
function in a study of 450 people with knee OA4.
Despite these initial promising successes, the U.S. Food and
Drug Administration (FDA) put on hold the trials in OA due to
concerns over accelerated rates of OA progression leading to
osteonecrosis, accelerated loss of joint space (rapid progressive OA
Type I) or rapid joint destruction and bone substance loss (rapid
progressive OA Type II) leading to total joint replacement5. The
mechanism of these events is unclear but joint adverse events
were observed particularly in patients using a-NGFs in combina-
tion with non-steroidal anti-inﬂammatory drugs (NSAIDs), sug-
gesting that the signiﬁcantly greater analgesic effect of these
separate classes of drugs prompted patients to permit increased
joint load without experiencing the usual pain that would limit
joint stress1,5. Development of a-NGF drugs is continuing with
stringent safety criteria included in future trials as a-NGF therapiesy International.
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Potential imaging joint safety ﬁndings and exclusionary criteria for
eligibility for the large weight bearing were presented in parts I
and II of this atlas.
The shoulder as a non-weight bearing joint is likely to be less
affected by increased loading due to efﬁcacious pain reduction.
However, it remains prone to degeneration especially due to
concomitant rotator cuff pathology and previous trauma and in-
ﬂammatory disorders. Overall shoulder OA is less prevalent than
knee or hip OA with the strongest risk factor being age6 and with
osteonecrosis being a relevant contributor to subsequent shoulder
OA7.
Aim of this third part of the atlas is to illustrate imaging
ﬁndings relevant for eligibility and potential joint safety ﬁndings
such as osteonecrosis, incidental ﬁndings such as large cystic le-
sions, inﬂammatory disorders, bone marrow disorders and
metastases.
Methods
This part of the atlas is based on eight in-person and 20þ
teleconference meetings of four experienced musculoskeletal ra-
diologists (FWR, CH, KH, AG) and a senior imaging expert (CGM)
representing a contract research organization (CRO) active in a-
NGF studies to deﬁne potential eligibility and safety ﬁndings
relevant for a-NGF clinical trials. 250þ baseline and follow-up
radiographic and Magnetic resonance imaging (MRI) image ex-
amples of shoulder joints were reviewed in consensus to deﬁne
the most relevant and characteristic imaging ﬁndings of entities
that may be encountered during a-NGF studies at screening or
during the course of a study. Images for this atlas were derived
from personal teaching and training ﬁles of these radiologists.Results
Osteonecrosis of the shoulder is rare but may be more
commonly encountered in patients with sickle cell disease with a
high likelihood of progressing to humeral head collapse8. Incidence
of humeral head involvement in an osteonecrosis patient cohort
was 7% of all osteonecrosis patients, with a high incidence of
concomitant or previous corticosteroid use (82%) of osteonecrosis
of the hip (81%), and bilateral disease (74%)9. Osteonecrosis of the
humeral head should be suspected in patients presenting with
shoulder pain and a history of osteonecrosis in other joints9.
Figure 1 presents early ﬁndings of humeral head osteonecrosis only
visible on MRI with the humeral articular surface still preserved.
Figure 2 illustrates more advanced stages of osteonecrosis with
humeral articular surface collapse and marked secondary inﬂam-
matory response. Figure 3 represents ﬁndings of humeral head
deformity and destruction either due to neuropathic arthropathy or
hydroxyapatite formation leading to rapid progression and joint
destruction, also called Milwaukee shoulder10,11. In addition sec-
ondary OA in osteonecrosis is visualized that include humeral head
deformity and osteophyte formation. Figure 4 represents examples
of anatomical variants such as glenoid dysplasia leading to OA and
potential secondary inﬂammatory response characterized as sy-
novitis and joint effusion on MRI. Figure 5 shows examples of post-
traumatic OA and rotator cuff arthropathy leading to large osteo-
phyte formation and humeral headmigration. In addition examples
of rheumatoid arthritis and chondromatosis are shown12. Large
cystic lesions are presented in Fig. 6. Benign appearing cystic le-
sions are not an exclusionary diagnosis at eligibility unless they
increase potential fracture risk. Figure 7 represents examples of
focal and diffuse osseous malignancy that are exclusionary di-
agnoses at eligibility and on-study.
Fig. 1. Osteonecrosis of the shoulder. A. Anterioreposterior radiograph does not show any abnormalities. Regular articular surface contours and unremarkable humeral osseous
structure is depicted. B. Sagittal proton density-weighted fat suppressed MR image exhibits focal areas of epiphyseal osteonecrosis ARCO* grade II (arrows). C. Coronal T1-weighted
image of another patient shows focal subchondral area of demarcated osteonecrosis (arrows) with fat-equivalent center. D. Corresponding proton-density weighted fat suppressed
image visualizes area of osteonecrosis as subchondral hyperintensity (arrows) with central hypointensity.
*ARCO (Association Research Circulation Osseous): committee on terminology and classiﬁcation). ARCO News 1992; 4:41e46.
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Fig. 2. Osteonecrosis of the shoulder. A. Sagittal proton density-weighted fat suppressed MRI shows post-traumatic deformity of the humeral head and well-demarcated sub-
chondral area of osteonecrosis ARCO grade II (arrow). B. Anterioreposterior radiograph of the shoulder shows osteonecrosis ARCO grade III with humeral head surface deformity
depicting subchondral collapse (arrows). C. Coronal T1-weighted MR image shows marked deformation of humeral head (arrows) and sclerosis of articulating glenoid (asterisk).
Note subarticular circumscribed necrotic area of humeral head (small arrows). Finding is consistent with articular surface collapse and advanced osteonecrosis ARCO grade IV. D.
Corresponding coronal T1-weighted fat suppressed contrast-enhanced image shows marked synovial activation and synovitic thickening of joint capsule (arrows). Note marked
concomitant hyperintense bone marrow edema (asterisk).
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Fig. 3. Secondary joint deformity. A. Baseline radiograph shows regular articulation within the gleno-humeral joint without signs of OA. B. Same shoulder 3 months later shows
marked deformity of humeral head and bone loss also of glenoid due to rapid progressive neuropathic arthropathy. C. Complete disintegration of humeral head (arrows) as a
consequence of rapid destructive crystal arthropathy (hydroxyapatite e Milwaukee* shoulder). Arrows point to humeral head osseous remnants. D. Deformity of humeral head
surface contour (arrows) in this gleno-humeral joint is a consequence of osteonecrosis. Note osteophyte formation at the inferior humeral head.
*McCarty DJ, Halverson PB, Carrera GF, Brewer BJ, Kozin F. “Milwaukee shoulder” e association of microspheroids containing hydroxyapatite crystals, active collagenase, and neutral
protease with rotator cuff defects. I. Clinical aspects. Arthritis Rheum 1981; 24:464e473. Genta MS, Gabay C. Images in clinical medicine. Milwaukee shoulder. N Engl J Med 2006;
354:e2.
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Fig. 4. Advanced OA due to anatomical variants. A. Anterioreposterior radiograph of gleno-humeral joint shows marked dysplasia of glenoid without evident signs of OA. B.
Corresponding axial fat suppressed proton density-weighted MR image depicts marked cartilage loss at posterior aspect of glenoid (arrows) representing early signs of OA not
revealed by radiography. C. Axial CT image of a different patient with glenoid dysplasia shows severe narrowing of joint space (arrows) and periarticular sclerosis. Note deformity of
humeral head and glenoid. D. Corresponding axial ﬂuorodeoxyglucose - positron emission tomography (FDG-PET) image depicts markedly increased glucose uptake within the joint
space reﬂecting synovitis and explaining incident pain in this patient (arrows).
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Fig. 5. Advanced OA of the shoulder. A. Post-traumatic OA characterized by large inferior humeral osteophyte (large arrows) and severe joint space narrowing (small arrows).
Finding per se is not an adverse event but rather representing pre-existing joint damage. B. Rotator cuff arthropathy characterized by signs of OA (inferior humeral osteophyte e
arrow) and cranial subluxation of humeral head due to large supraspinatus tendon tear. C. Advanced secondary OA due to rheumatoid arthritis with diffuse gleno-humeral cartilage
loss and large erosive subchondral cystic alterations (arrow). Note characteristic rice-bodies and effusion in the subdeltoid bursa (asterisk). D. Synovial chondromatosis with
multiple intraarticular chondroid loose bodies in the synovial cavity (arrows). In addition cartilage loss and cranialization of humeral head is shown.
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Fig. 6. Cystic lesions. A. Benign cystic lesions are not a diagnosis of exclusion at eligibility if they are not considered to increase fracture risk. Coronal proton density-weighted fat
suppressed image depicts glenoid ganglion cyst (thin arrows). Note incidental ﬁnding of a small full-thickness supraspinatus tendon tear (thick arrow). B. Corresponding radiograph
shows lucency at the inferior glenoid (arrow). C. Another patient with a large intra-osseous benign-appearing cystic lesion depicted on this T1-weighted coronal MR image (arrows).
D. Axial proton-density weighted image shows cyst as well-circumscribed hyperintense lesion (arrows). No signs of malignancy are observed.
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Fig. 7. Incidental osseous ﬁndings relevant for eligibility and safety but undetectable by X-ray. A. Incident painful shoulder. T1-weighted coronal MR image shows well-
circumscribed hypointense lesion in the metaphyseal humeral shaft (arrow) in a patient with history of breast cancer. Finding likely not responsible for pain as there is
concomitant supraspinatus tendon pathology. B. Corresponding proton density-weighted fat suppressed image depicts ﬁnding as hyperintense lesion (large arrow). Lesion is
suspicious of metastasis, which was conﬁrmed by increase in size in a short interval after 3 months. Note that there is an undersurface articular-sided partial supraspinatus tear
close to the tendon attachment (small arrows). C. Normal signal intensity of bone marrow is shown on coronal fat suppressed proton-density-weighted image in this example. D.
However, corresponding T1-weighted MR image exhibits marked diffuse hypointensity consistent with marrow inﬁltration. A diagnosis of acute lymphatic leukemia was estab-
lished shortly after. Sensitivity of T1-weighted images for marrow assessment is exempliﬁed in this image.
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